Featured Research

from universities, journals, and other organizations

Fox Chase Cancer Center Study Links Oxygen Levels And Angiogenesis In Prostate Cancer

Date:
October 25, 2000
Source:
Fox Chase Cancer Center
Summary:
A new study demonstrates a significant association between a lack of oxygen in prostate cancer cells and the increased expression of the angiogenesis marker, endothelial growth factor or VEGF. The lack of oxygen, called hypoxia, in tumor cells has been shown to correlate, not only with poor response to radiotherapy, but also to tumor aggressiveness.

PHILADELPHIA (October 23, 2000) -- A new study demonstrates a significant association between a lack of oxygen in prostate cancer cells and the increased expression of the angiogenesis marker, endothelial growth factor or VEGF. The Fox Chase Cancer Center study was presented at the American Society for Therapeutic Radiology and Oncology Annual Meeting in Boston, Mass. on October 23 at 10:45 a.m.

The lack of oxygen, called hypoxia, in tumor cells has been shown to correlate, not only with poor response to radiotherapy, but also to tumor aggressiveness.

"Prior studies have shown that cancer cells adapt to hypoxia by secreting angiogenic growth factors, such as vascular VEGF," explained James V. Tricoli, Ph.D., an associate member in the medical sciences division of Fox Chase and an author of the study. "The purpose of this study was to determine if increasing levels of hypoxia are associated with increased production of VEGF in prostate cancer."

In the study, the oxygen levels in prostate tumor cells were measured in 13 men undergoing radical prostatectomy. Each tumor comprised approximately 100 separate oxygen readings. Tumor tissue from the prostatectomy specimens was then analyzed to measure the level of VEGF. Using a published methodology, two independent observers (blinded to the oxygen data) scored the percent of cells staining positive for VEGF and the staining intensity. The significance of associations between oxygen levels and VEGF staining was determined by Pearson correlation.

"The blinded comparison of oxygen levels and VEGF staining intensity reveals a clear link between increasing hypoxia and VEGF," said Benjamin Movsas, M.D., director of clinical radiotherapy research at Fox Chase. "These findings support examining anti-angiogenic strategies in treating prostate cancer."

Fox Chase Cancer Center, one of the nation's first comprehensive cancer centers designated by the National Cancer Institute in 1974, conducts basic and clinical research; programs of prevention, detection and treatment of cancer; and community outreach. For more information about Fox Chase activities, visit the Center's web site at: http://www.fccc.edu.


Story Source:

The above story is based on materials provided by Fox Chase Cancer Center. Note: Materials may be edited for content and length.


Cite This Page:

Fox Chase Cancer Center. "Fox Chase Cancer Center Study Links Oxygen Levels And Angiogenesis In Prostate Cancer." ScienceDaily. ScienceDaily, 25 October 2000. <www.sciencedaily.com/releases/2000/10/001023204228.htm>.
Fox Chase Cancer Center. (2000, October 25). Fox Chase Cancer Center Study Links Oxygen Levels And Angiogenesis In Prostate Cancer. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2000/10/001023204228.htm
Fox Chase Cancer Center. "Fox Chase Cancer Center Study Links Oxygen Levels And Angiogenesis In Prostate Cancer." ScienceDaily. www.sciencedaily.com/releases/2000/10/001023204228.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins